IMPORTANCE Vitreous floaters are common and can worsen visual quality. YAG vitreolysis is an untested treatment for floaters. 
F loaters become more prevalent with age because of degenerative vitreous changes that occur throughout life. In youth, hyaluronan keeps collagen fibrils separated in the vitreous cavity and thus maintains transparency of the vitreous. However, with time, hyaluronan dissociates from collagen, causing cross-linking and aggregation of collagen with fibrous structures that scatter light-a process known as vitreous liquefaction. [1] [2] [3] Clinically, a posterior vitreous detachment (PVD) is often marked by a degree of fibroglial tissue known as a Weiss ring that is free floating over the optic nerve. A PVD allows the vitreous body to move when the head or eye moves, and thus, the Weiss ring and vitreous opacities cast shadows onto the retina that are perceived as floaters.
A PVD is present in approximately 65% of patients reaching the age of 65 years. 4, 5 Although most patients grow accustomed to the visual disturbance associated with Weiss rings and other floaters, many find them bothersome. 6 Floaters can reduce contrast sensitivity and quality of life. 7, 8 Three management options exist for symptomatic floaters: patient education and observation, pars plana vitrectomy with a 1-incision Intrector (in which a 1-incision, limited core vitrectomy is performed while visualizing through an indirect ophthalmoscope; Insight Instruments) or a standard 3-port vitrector, and YAG vitreolysis.
Existing literature assessing the effect of YAG laser on the properties of rabbit vitreous has suggested that pathologic disruption may occur with laser application in the middle or posterior vitreous. 9 There are limited published studies on the effect of YAG vitreolysis for treating symptomatic floaters in humans. Small, uncontrolled cases series 6,10,11 assessing YAG vitreolyisis report some symptomatic success and suggest a good safety profile. No prospective, sham-controlled trials have been performed, to our knowledge. This is particularly important because of the subjective nature of floater-related visual disturbance and the potential of placebo effect confounding the efficacy of treatment. Research by Karickhoff 12 showed the most robust outcomes when treating Weiss rings. Therefore, the current study evaluated YAG vitreolysis in patients with symptomatic Weiss rings.
Methods

Participants
This single-center, masked, sham-controlled randomized clinical trial included 52 patients (35 women and 17 men) at Ophthalmic Consultants of Boston, Boston, Massachusetts, from March 25, 2015 , through August 3, 2016 . All were patients of the practice with a primary symptom of symptomatic floaters. No patients were billed for participation in the study. Of the 52 participants, 36 were randomly assigned to unilateral treatment with YAG laser vitreolysis, and 16 were assigned to sham YAG vitreolysis (control). All were followed up for 6 months. In all cases, one eye (the eye with the most patient-determined floater-related symptoms) was treated, and the other eye was observed. Patients were assigned to YAG and sham groups in a 2:1 ratio to maximize the number of treated patients and obtain more robust efficacy and safety data for YAG vitreolysis ( Figure 1 ). All patients provided written informed consent before participating in the study, and all data were deidentified. The study was conducted in adherence to the tenets of the Declaration of Helsinki, and the methods and execution were consistent with the International Conference on Harmonisation guidelines for Good Clinical Practice. Study approval was obtained from the Sterling Institutional Review Board, Atlanta, Georgia. The trial protocol can be found in the Supplement 1. A priori sample calculations assumed a modest improvement in symptoms of 30% in the YAG group compared with 10% in the sham group, yielding a sample of 75 patients with an SD of 25%, α of .05, and power of 0.9. A planned interim analysis on January 20, 2016, showed a statistically significant difference among the 13 patients who had completed the study. Thus, the decision was made to schedule no further screening visits beyond those already scheduled, resulting in 52 enrolled patients.
Inclusion criteria were as follows: symptomatic Weiss ring floater secondary to PVD; floater symptom duration of at least 6 months; PVD documented on clinical examination, optical coherence tomography, and B-scan (all performed by the same examiner [one of us, C.P.S.]; if complete PVD was not visible for all 3 modalities, the patient was excluded); a self-rated visual disturbance of at least 4 on a 0-to 10-point scale, with 0 indicating no symptoms and 10 indicating debilitating symptoms; symptomatic Weiss ring (PVD) located at least 3 mm from the retina and 5 mm from the posterior lens capsule of the crystalline lens, as measured on B-scan (patients with pseudophakia had no minimum required distance from the intraocular lens) to maximize safety; ability to undergo YAG laser procedure; and acceptance of associated risks. Exclusion criteria were Snellen best-corrected visual acuity (BCVA) worse than 20/50 in the nonstudy eye; history of retinal tear, retinal detachment, uveitis, diabetic retinopathy, macular edema, retinal vein occlusion, or aphakia in the study eye; and history of glaucoma or high intraocular pressure, defined as a history of glaucoma surgery or currently taking 2 or more topical glaucoma medications in the study eye.
All patients were followed up for 6 months, with clinical examinations performed at postoperative week 1, month 1, month 3, and month 6. The primary outcomes measured at 6 months included subjective percentage of improvement (from 0% to 100%), 6 10-point visual disturbance score as described by Singh, 13 5-level qualitative scale described by Delaney et al, 6 and the National Eye Institute Visual Functioning Questionnaire 25 (NEI VFQ-25). Of these, the NEI VFQ-25 was the only validated self-reporting method. Secondary outcomes included objective change based on masked grading of color wide-angle fundus photography, 6 Early Treatment Diabetic
Retinopathy Study (ETDRS) BCVA, and adverse events.
Preoperative Evaluation and Randomization
Before treatment, all patients completed a nonvalidated baseline questionnaire, which asked the following 6 : (1) How long have you had symptomatic floaters? (2) Do you have symptomatic floaters in the right, left, or both eyes? (3) Which eye is more symptomatic: right or left or both equally symptomatic? (4) How many floaters do you have in the more symptomatic eye (or the study eye if both eyes were equally affected)? (5) What activity is most inconvenienced by floater presence? (6) Rate your visual disturbance by floaters on a 0-to 10-point scale, with 0 indicating no symptoms and 10 indicating debilitating symptoms. Patient age, sex, and lens status were recorded. The ETDRS BCVA was determined preoperatively along with a B-scan. Spectralis optical coherence tomography and infrared photography (Heidelberg Engineering), color photography (Optos plc), and slitlamp and indirect ophthalmoscope examination with scleral depression were conducted at baseline. Status of preexisting macular pathologic findings was not recorded. The same study coordinator administered the NEI VFQ-25 at baseline (and again at month 6) for all patients.
Surgical Procedure
One of us (C.P.S.) performed all the surgical procedures. YAG vitreolysis was performed using the Ultra Q Reflex laser (Ellex Medical). A maximum energy per pulse of 7 mJ was used, as described by Tsai et al. 11 The energy was initially set at 3 mJ and titrated to an appropriate level at which the surgeon observed plasma formation with the creation of gas bubbles. After intraocular pressure was measured, the pupil of the study eye was dilated with phenylephrine, 2.5%, and tropicamide, 1%. Proparacaine was given, and an Ocular Karickhoff 21 mm Vitreous Lens with goniosol was applied before YAG laser administration. The number of laser shots given per patient was at the discretion of the treating physician, but in all cases, laser application ceased after vaporization of the Weiss ring and all other visually significant floaters. Patients received only 1 laser treatment session to prevent unmasking of controls. Participants in the sham group underwent similar treatment; they were fitted with a sham lens that had a lens filter glued to the surface to prevent YAG energy from passing through the lens. The YAG laser energy was at its lowest setting of 0.3 mJ. Patients were not asked to which group they believed they were randomized.
Postoperative Assessment
No topical therapy was given postoperatively. Intraocular pressure was measured at 30 minutes postoperatively. At postoperative week 1, month 1, and month 3, all patients underwent repeated assessment with non-BCVA slitlamp and indirect ophthalmoscopy with scleral depression of study eye and applanation tonometry. At postoperative month 6, all patients completed the NEI VFQ-25 and a questionnaire to assess their floater symptoms with the following questions: (1) The ETDRS BCVA, color photography, optical coherence tomography, infrared photography, and slitlamp and indirect ophthalmoscopy with scleral depression of the study eye and applanation tonometry were performed again at postoperative month 6. One of us (J.S.H.) graded the masked wideangle photographs for the presence of floaters by using the same 5-level qualitative scale used by patients to self-report their postoperative symptoms compared with baseline. One of us (J.S.H.) used the following percentages to quantify the level of improvement: worse, less than 0%; same, 0%; partial success, 30% to 50%; significant success, 50% to 70%; and complete success, 100%. 
Statistical Analysis
Continuous outcome variables were compared between treatment groups with a 2-sample t test and within treatment groups using a paired t test (Excel, Microsoft Corporation). The 5-level qualitative scale was analyzed as the proportion reporting significant or complete resolution using a 2-sample test of proportion (Stata version 12.1, StataCorp). P < .05 was considered to be statistically significant.
Results
Fifty-two patients (52 eyes; 17 men and 35 women; 51 white and 1 Asian) with symptomatic Weiss rings were enrolled; all were followed up for 6 months. The mean (SD) age of participants was 61.4 (8.0) years in the YAG group and 61.1 (6.6) years in the sham group (age range, 34-77 years; median age, 62 years). The 36 eyes treated with YAG laser vitreolysis (69% phakic) received a mean of 218 laser shots with a mean power of 1316 mJ. Mean duration of symptomatic floaters was 6.7 years (range, 0.5-63.0 years; median, 2.0 years) in the YAG group and 5.0 years (range, 0.5-30.0 years; median, 3 years) in the sham group.
Improvement
The YAG group reported significantly greater improvement in self-reported floater-related visual disturbance (54%) compared with sham controls (9%) (difference, 45%; 95% CI, 25%-64%; P < .001) (eFigure in Supplement 2). There was no appreciable learning curve effect with YAG vitreolysis; the first 10 patients reported similar improvements as the last 10 patients (54% vs 55%; P = .93).
Visual Disturbance Score on a 10-Point Scale
The YAG group had greater improvement in the visual disturbance score (improvement, 3.2) than did the sham group (improvement, 0.13) (difference, −3.0; 95% CI, −4.3 to −1.7; P < .001) ( Table 1) .
Symptoms on a 5-Level Qualitative Scale Figure 2 shows that 19 of 36 patients (53%) in the YAG group reported their symptoms as significantly or completely better after treatment vs 0 in the sham group (difference, 53%; 95% CI, 36%-69%; P < .001). Table 2 shows that the YAG group reported significantly better general vision (69.4 vs 53.1; difference, 16.3; 95% CI, 0.9-31.7; P = .04) and peripheral vision (94.4 vs 82.8; difference, 11.6; 95% CI, ; P = .04) and fewer role difficulties (93. 1 vs 75.8; difference, 17.3; 95% CI, ; P < .001) and dependency on others (98.8 vs 93.2; difference, 5.6; 95% CI, 0.4-10.8; P = .03) than did sham controls at 6 months. Figure 2 shows that 34 of 36 patients (94%) in the YAG group had significantly improved or completely resolved floaters compared with 0 in the sham group (difference, 94%; 95% CI, 87%-102%; P < .001). This objective 95% improvement was significantly greater than the subjective patient-reported improvement of 53% (P < .001). Table 3 lists the visual acuity at baseline and 6 months for the YAG and sham groups. There was no change in ETDRS BCVA regardless of treatment group. In the YAG group, the visual acuity letter score was 81.7 (approximately 20/25) at baseline and 81.6 (approximately 20/25) at 6 months (P = .84). In the sham group, the visual acuity letter score was 81.9 (approximately 20/25) at baseline and 81.4 (approximately 20/25) at 6 months (P = .71). The BCVA changed by −0.2 letters in the YAG group and by −0.6 in the sham group (difference, 0.4; 95% CI, −6.5 to 5.3; P =. 94).
NEI VFQ-25 Scores
Objective Change in Masked Grader Photographs
ETDRS BCVA
Adverse Events
No retinal tears, retinal detachments, elevated intraocular pressure, or other significant adverse events occurred in the YAG group by postoperative month 6. One posterior chamber intraocular lens was pitted peripherally with the YAG laser when anterior floaters were treated, although this finding was not 
Discussion
The current study revealed moderate improvement in floater symptoms with a single laser session by postoperative month 6. Every subjective outcome measure in this study was aligned, supporting the efficacy of YAG vitreolysis. Patients typically believed that their floaters were 54% improved after a single treatment, with 53% of patients reporting significant or complete resolution of symptoms at postoperative month 6. Several measures of quality of life also improved compared with those in the sham laser group, including general vision and independence. The YAG group reported numerous improvements 6 months after treatment, including in near and distance activities and mental health. These findings appear to show better efficacy than those reported in an analysis of 39 patients treated for PVD-related floaters by Delaney et al. 6 They used a maximum pulse energy of 1.2 mJ with a mean power of 310.4 mJ per session. There were no complications after a mean of 1.62 treatment sessions and 26.6 months of follow-up. Only 38% of patients reported moderate or significant benefit from the treatment, defined as an improvement of at least 30% from baseline. 6 The difference between the present study and the study by Delaney et al 6 may relate to the mechanism by which YAG vitreolysis removes floaters. YAG works by vaporizing floaters caused by plasma formation, which may not be appreciated at the low power levels used by Delaney et al. 6 At lower power levels, the vitreous is fractionated but not vaporized. In the present study, patients in the sham group reported a 9% improvement in symptoms at 6 months (range, 0%-60%; median, 0%), and 5 of the 16 patients (31%) in the sham group reported between 20% and 60% improvement in their floater symptoms. This finding suggests a small placebo effect with YAG vitreolysis or possibly relates to the effect of time.
This study observed noticeable discrepancies between the masked grading of photographs by one of us (J.S.H.) and patients' subjective responses. There are several possible explanations, including that the treating surgeon did not appropriately manage patient expectations; patients particularly disturbed by vitreous floaters may have high visual demands and thus have unrealistic visual expectations after YAG vitreolysis; and YAG vitreolysis may reduce the appearance of a Weiss ring on color photography, but patients remain bothered by other vitreous opacities not revealed by photography. To illustrate, of 8 patients who reported 0% improvement after YAG vitreolysis, one of us (J.S.H.) reported 100% improvement in 4 and 50% to 70% improvement in 3. Objectively identified worsening of floaters occurred in 1 case. This patient had a progressive floater duet (a Weiss ring plus fluffy anterior, inferior floaters) and was the only patient who underwent vitrectomy (no patients in the sham group underwent vitrectomy at a later date). The 7 other patients described small residual postoperative floaters. Although comparative photographs showed that their Weiss ring had improved after YAG treatment, these patients believed that the presence of residual floaters was just as bothersome as the original Weiss ring.
No adverse events judged to be of clinical relevance occurred after YAG laser vitreolysis in this small prospective study, which was underpowered to identify less common potential complications. However, with use of the rule of 3, there is 95% confidence that there is no greater thana1in12(8.3%)risk of a serious adverse event after YAG vitreolysis.
Limitations
The current study has several limitations, including its small sample size and short follow-up period. Larger studies with the same design are needed to corroborate the reported findings. Longer follow-up is required to determine the long-term stability of results and the degree of adverse events associated with the procedure. The current study focused on comparing YAG vitreolysis with sham but not with vitrectomy. Although such a comparison fell beyond the scope of this study, a future study comparing small-gauge vitrectomy with YAG vitreolysis would help illuminate the benefits and risks of each procedure. Similarly, although observation alongside patient education is the most common management approach for floaters, the current study did not include an observation arm to prevent unmasking patients in each treatment arm.
The current study also allowed just 1 treatment session per patient to prevent unmasking. However, this strategy may not reflect real-world treatment, in which patients may be treated with additional YAG vitreolysis sessions for persistent floaters after initial treatment. Furthermore, results from this study cannot be generalized to all patients with symptomatic floaters because only those with Weiss rings arising from PVD were treated.
Conclusions
For patients presenting with visual disturbance secondary to a clinically confirmed Weiss ring, the current study suggests that YAG vitreolysis improves short-term visual outcomes, both subjectively and objectively, without adverse events judged to be clinically relevant. Author Contributions: Dr Shah had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Shah. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: Shah. A screening visit is required and will take place on the same day as the start of 77 the research study to determine if you qualify and are willing to participate. If the 78 study doctor decides you are qualified and you agree to participate in this study, 79 you will receive either the YAG laser procedureor sham laserprocedure, followed 80 by check-ups one week, one month, three months, and six months after your 81 procedure. The study duration is a total of 6 months. 82 83
STUDY PROCEDURES 84
Should you decide to participate, you will first sign this Subject Information and 85 Consent Form before any study-related procedures are performed. You will be 86 asked about your medical history, family history, and demographic information.
87
The following is a description of the procedures that will be performed during this 88 study: 89 90
Eye Exams 91
At each visit you will have an eye examination. Your vision will be checked at 92 each study visit. You will receive a numbing eye drop so that the eye pressure 93 can be checked. The fluid pressure in the eye will be checked with a device 94 called applanation tonometry. Your pupils will be dilated with eye drops so that 95 the study doctor can examine your eye (slit lamp/indirect ophthalmoscopy). The 96 study doctor will then use special lenses to look at your retina under high 97 magnification and will gently push on the outside of the eye during exam (scleral 98 depression). laserprocedure. You will not know which group you will be a part of. The laser 116 procedure will begin with a numbing drop placed into the eye. Then a lens will be 117 placed on the eye to focus the laser. The laser will then be performed.
118
Afterwards, the lens will be removed and the fluid pressure inside the eye will be 119 checked 30 minutes after the procedure using a device called applanation 120
tonometry As part of this study, Dr. Shah, the Study Doctor, and his team at the research 217 facility will keep records of your participation in this study. These study records 218 will include personal information that you provide including your age, sex, etc., 219 the results of procedures and tests you undergo during the study or had before 220 the study, information about your response to treatments you receive under the 221 study, and other medical information relating to your participation in the study.
222
Under federal law your study records cannot be used or disclosed for research 223 purposes unless you sign this authorization. You may not participate in the study 224 unless you sign this authorization. If you sign this informed consent form, you will 225 be agreeing to the disclosures described below: 226 227 a. Your study records and medical records may also be reviewed by Sterling 228
Institutional Review Board which is an ethics committee that reviews the 229 conduct of human research studies.
231
The research facility and the Sterling Institutional Review Board will review and 232 use your study records only for purposes of this study. They will keep your 233 identity confidential and, except for the disclosures described above, will not 234 disclose your study records to other parties unless disclosure is required by law.
235
Once the research facility discloses information in your study records or medical 236
Page 8 CONFIDENTIAL records to the Sponsor or its consultants, the information will no longer be 237 protected by federal law. Because of the need to release information to these 238 parties, absolute confidentiality cannot be guaranteed. However, the investigator 239 will only use your information for purposes of the study and will not disclose your 240 study records to parties unless disclosure is required by law. If reports or articles 241 are written about the study, you will not be identified by name in them. Your study 242 records may be retained at the research facility indefinitely following the 243 completion of the study. You will not have the right to review your records while 244 the research is in progress. However, you will be able to review your records 245 after the research has been completed.
247
This authorization has no expiration date. However, you have the right to revoke 248 this authorization at any time. You can do this by giving written notice to the 249 study doctor, informing them that you are revoking your authorization to use and 250 disclose medical information. The study doctor's contact information is on page 251 1 of this document.
253
If you revoke this authorization to use and disclose your medical information, you 254
will not be permitted to continue your participation in the study after the 255 revocation.
If you drop out of the study, you do not have to revoke your 256 authorization to use and disclose your medical information. However, if you drop 257 out of the study and do decide to revoke your authorization to use and disclose 258 your medical information, the information that has already been collected in your 259 study record may continue to be used and disclosed as described above, 260 however, no new information will be obtained or added. Sham laser treatment will be applied under the same procedure used for laser treatment but without switching on the laser beam and by imitating depression of the laser pedal.
ENDPOINT(S)
Primary:
To determine patients' subjective improvement in floater symptoms based on the floater-specific Page 14 CONFIDENTIAL questionnaire.
Secondary:
• The following procedures will be implemented to minimize the risk of potential adverse 625 events associated with YAG laser treatment of Weiss ring. 626
Verify study eye 627
Instill 2 drops of 0.5% proparacaine hydrochloride into the study eye 628
Fill Karickoff lens half-way with goniosol 629
For YAG laser treatment: 630
Single shot mode with a maximum pulse energy of 7 mJ per pulse. The treating 631 physician will start at 1 mJ and titrate up until he/she reaches enough power to achieve 632 disruption of the Weiss ring. 633
The endpoint of treatment is the disruption of the Weiss ring into smaller fragments as 634 well as any other vitreous opacities deemed visually significant by the treating physician. 635
Only one treatment session will be performed. 
